Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Obs and Gynae
    • Antibiotic Guideline...

    Antibiotic Guideline For Obstetrics And Gynaecological Infections:GOI

    Written by supriya kashyap kashyap Published On 2016-08-18T13:50:22+05:30  |  Updated On 18 Aug 2016 1:50 PM IST
    Antibiotic Guideline For Obstetrics And Gynaecological Infections:GOI

    In 2016 National Centre For Disease Control, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India came out with National Treatment Guidelines for Antimicrobial Use in Infectious Diseases.



    Following are major recommendations for Obstetrics And Gynaecological Infections:






    • Fluoroquinolones are contraindicated in 1st trimester.

    • Cotrimoxazole is contraindicated in 1st trimester.

    • Doxycycline is not recommended in nursing mothers. If need to administer doxycycline discontinuation of nursing may be contemplated.





























    InfectionsLikely organismPrimary treatment (presumptive antibiotics)Alternate treatmentRemarks
    Asymptomatic Bacteriuria > 1,00,000 cfu/ ml of bacteria of same species in 2 urine cultures obtained 2-7 days apart.

    Treat as per sensitivity result for 7 days.
    Nitrofurantoin 100 mg Oral, BD for 7 days

    or Amoxicillin 500 mg Oral BD x 7-10 days .
    Oral cephalosporins, TMP-SMX or TMP aloneScreen in 1st trimester. Can cause pylonephritis in upto 25% of all pregnant women. 30 % Chance of recurrence after empirical therapy 1. Few direct effects, uterine hypo perfusion due to maternal anemia dehydration, may cause fetal cerebral hypo perfusion.

    2. LBW, prematurity,premature labour, hypertension, preeclampsia, maternal anemia, and amnionitis. Need to document pyuria (Pus cells > 10/HPF)
    Group B streptococcal Disease, Prophylaxis and TreatmentGroup B StreptococciIV Penicillin G 5 million units. (Loading dose) then 2.5 -3 million units IV QID until delivery.

    or

    Ampicillin 2 gm IV ( Loading dose) then 1 gm QID until delivery
    Cefazolin 2 gm IV (Loading Dose) and then 1 gm TID

    Clindamycin 900 mg IV TID or vancomycin IV or teicoplanin for penicillin allergy
    Prevalance very low so the prophylaxis may be required only on culture documented report Associated with high risk of pre-term labour,still birth,neonatal sepsis
















    ChorioamnionitisGroup B streptococcus, Gram negative bacilli, chlamydiae, ureaplasma and anaerobes, usually PolymicrobialClindamycin/ vancomycin/ teicoplanin and cefoperazone-sulbactum

    If patient is not in sepsis then IV Ampicillin
    Preterm Birth, 9-11% death rate in preterm infant’s unfavourable neurologic outcome, lesser risk to term infants.

































    Septic abortionBacteroides, Prevotella bivius, Group B, Group A Streptococcus,

    Enterobactereaceae, C. trachomatis, Clostridium perfringens.
    Ampicillin 500 mg QID +Metronidazole 500mg IV TDS if patient has not taken any prior antibiotic (start antibiotic after
    sending cultures) If patient has been partially treated with antibiotics, send blood cultures and start PiperacillinTazobactam or Cefoperazonesulbactam till the sensitivity report is available.
    Ceftriaxone 2g IV

    OD
    Endomyometritis

    and Septic Pelvic

    Vein Phlebitis
    Bacteroides, Prevotella bivius, Group B, Group A Streptococcus, Enterobactereaceae, C. trachomatis, Clostridium perfringensSame as above.
    Obstetric Sepsis during pregnancyGroup A beta-haemolytic Streptococcus, E.coli, anaerobes.If patient is in shock and blood culture reports are pending, then start

    Piperacillin-Tazobactam

    or

    Cefoperazone-sulbactam till the sensitivity report is available and modify as per the report. If patient has only fever, with no features of severe sepsis start amoxicillin clavulanate oral 625TDS/IV 1.2 gm TDS Or

    Ceftriaxone 2gm IV OD+ Metronidazole 500mg IV TDS +/-gentamicin 7mg/kg/day OD

    if admission needed. MRSA cover may be required if suspected or colonized (Vancomycin/ Teicoplanin)
    Obstetric Sepsis following pregnancyS. pyogenes,

    E. coli,

    S. aureus

    S. pneumoniae, Meticillin-resistant

    S. aureus (MRSA),

    C. septicum & Morganella morganii.
    Same as aboveSources of sepsis outside Genital tract Mastitis UTI Pneumonia Skin and soft tissue (IV site, surgical site, drain site etc.)













    SyphillisRefer to STD program guidelines












    Tuberculosis in pregnancySimilar to NON PREGNANT population with some exceptions (see comment and chapter 8)Please refer RNTCP guideline

    WHO has advocated that, all the first line drugs are safe in pregnancy and can be used except streptomycin. SM causes significant ototoxicity to the fetus (Pyrazinamide not recommended by US FDA)

    1. Mother and baby should stay together and the baby should continue to breastfeed.

    2. Pyridoxine supplementation is recommended for all pregnant or breastfeeding women taking isoniazid as well as to neonate who are being breast fed by mothers taking INH.
    Very small chance of transmission of infection to fetus.

    Late diagnosis can predispose to LBW, prematurity.









    VIRAL INFECTIONS (NO ANTIBIOTICS TO BE GIVEN)













    Influenza In pregnancy (seasonal And H1N1)

    The best preventive strategy is administration of single dose of killed vaccine.
    Oseltamivir 75 mg Oral BD for 5 daysNebulization with Zanamvir respules (2) 5 mg each, BD for 5 days1. Tendency for severe including premature labor &delivery.

    2. Treatment should begin within 48 hrs of onset of symptoms.

    3. Higher doses commonly used in non pregnant population (150 mg) are not recommended in pregnancy due to safety concerns.

    4. Chemoprophylaxis can be used in significant exposures.

    5. Live (nasal Vaccine) is contraindicated in pregnancy.
    Direct fetal infection rare Preterm delivery and pregnancy loss.












    Varicella >20 wks of gestation, presenting within 24 hours of the onset of the rash,

    Aciclovir 800mg Oral 5 times a day IV acyclovir recommended for the treatment of severe complications,

    > 24 hrs from the onset of rash, antivirals are not found to be useful.
    VZIG should be offered to susceptible women < 10 days of the exposure. VZIG has no role in treatment once the rash appears.

    The dose of VZIG is 125 units / 10kg not exceeding 625 units, IM.
    Chickenpox during pregnancy does not justify termination without prior prenatal diagnosis as only.

    A minority of fetuses infected develop fetal

    varicella syndrome.









    PARASITIC INFECTIONS












    Acute Toxoplasmosis

    in pregnancy
    <18 weeks gestation at diagnosis-

    Spiramycin 1 gm Oral qid until 16-18 weeks/Pyrimathamine + sulphadizine. Alternate every two weeks–

    If PCR Positive -

    >18 weeks gestation and documented fetal infection by positive amniotic fluid PCR.

    Pyremethamine 50 mg Oral BD x 2 days then 50 mg OD +

    Sulphadiazine 75 mg/kg Oral x 1 dose then 50mg/kg bd

    +

    Folinic Acid (10-20 mg Oral daily) for minimum of 4 weeks or for duration of pregnancy.










    Malaria In pregnancy As per national program









    GENITAL TRACT INFECTIONS
















































    CandidiasisCandida speciesFluconazole oral 150 mg single dose For milder cases-

    Intravaginal agents as creams or suppositories clotrimazole, miconazole, nystatin. Intravaginal azoles, single dose to 7-14 days.
    Non-pregnant- If recurrent candidiasis, (4 or more episodes/year) 6 months suppressive treatment with fluconazole 150 mg oral once a week or clotrimazole vaginal suppositories 500 mg once a week.
    Bacterial vaginosisPolymicrobialMetronidazole500mg Oral BD x 7 days

    Or metronidazole vaginal gel 1 HS x 5 days

    Or Tinidazole 2 g orally ODx 3 days

    Or 2% Clindamycin Vaginal cream 5 gm HS x 5 days
    Treat the partner.
    TrichimoniasisTrichomonas vaginalisMetronidazole 2 gm single dose or 500 mg Oral BD X 7 days or

    Tinidazole 2 gm Oral single doseFor treatment failure – retreat with Metronidazole 500 mg Oral BD X 7 Days, if 2nd failure Metronidazole 2 gm Oral OD X 3- 5 days
    Treat sexual partner with metronidazole 2 gm single dose
    Cervicitis /Urethritis Mucopurulent gonoccocalPolymicrobialCeftriaxone 250 mg IM Single dose + Azithromycin 1 gm single dose OR Doxycycline 100mg BD x 7 day
    Pelvic Inflammatory Disease (Salpingitis & tubo-ovarian abscess)S. aureus, Enterobacteriacae, gonococci, gardenellaOutpatient treatment

    Ceftriaxone 250 mg IM/IV single dose plus +/- Metronidazole 500 mg BD x 14 days Plus Doxycycline 100 mg BD x 14 Days

    Inpatient Treatment Clindamycin +ceftriaxone till patient admitted then change to OPD treatment
    Drainage of tuboovarian abscess wherever indicated Evaluate and treat sex partner
    Mastitis without abscessS. aureusAmoxycillin clavulunate/Cephalexin 500 mg QID/ OR Ceftriaxone 2 gm OD OR MRSA- based on sensitivities Add Clindamycin 300 QID or

    Vancomycin I gm IV 12 hourly /teicoplanin 12mg/kg IV 12 hourly x 3 doses followed by 6 once daily IV
    Mastitis with abscessDrainage with antibiotic cover for MRSA

    Clindamycin 300 QID or

    Vancomycin 15mg/kg IV 12 hourly (maximum 1gm 12 hourly)/teicoplanin 12mg/kg IV 12 hourly x 3 doses followed by 6 mg once daily IV


    You can read the full Guideline by clicking on the following link :


    http://www.ncdc.gov.in/writereaddata/linkimages/AMR_guideline7001495889.pdf

    Directorate General of health servicesGovernment of IndiaIndia Antibiotic Guidelineinfectious diseaseMinistry of Health &amp; Family WelfareNational Centre For DiseaseObstetrics And Gynaecological Infections

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok